Related Guides
Continue your research with these related independent reviews.
Compounded Liraglutide: The Original GLP-1 for Obesity, Now Available Through Telehealth
Liraglutide (Saxenda) was the first GLP-1 receptor agonist approved for obesity in 2014 — five years before semaglutide. It still works, but newer agents have surpassed it on efficacy. Compounded liraglutide is now available through select telehealth providers for patients who need or prefer it.
Quick reference
Drug class
GLP-1 RA
Weight loss (SCALE)
~8% at 56 wks
Dosing schedule
Daily injection
Max dose (Saxenda)
3.0 mg/day
Context: Most new patients today are prescribed semaglutide or tirzepatide due to their superior efficacy (~15–21% weight loss vs ~8% for liraglutide). Compounded liraglutide is most relevant for patients transitioning from branded Saxenda or with specific clinical reasons to use liraglutide over newer agents. If you're starting fresh, see our tirzepatide vs semaglutide comparison first →
What Is Liraglutide?
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — the same drug class as semaglutide and tirzepatide, but an older molecule. Novo Nordisk developed two branded liraglutide products:
| Brand | Indication | Doses | FDA Approval |
|---|---|---|---|
| Victoza | Type 2 diabetes | 1.2mg, 1.8mg daily | Approved 2010 |
| Saxenda | Obesity / weight management | Up to 3.0mg daily | Approved 2014 |
Liraglutide has a shorter half-life than semaglutide (~13 hours vs ~1 week), which is why it requires daily injection versus once-weekly for semaglutide. The shorter half-life also means less stable drug exposure between doses, which may contribute to its lower efficacy compared to longer-acting agents.
How Liraglutide Compares to Newer GLP-1 Agents
| Medication | Weight Loss (Trial) | Dosing | Class | FDA Approved (Obesity) |
|---|---|---|---|---|
| Liraglutide (Saxenda) | ~8% (SCALE, 56 wks) | Daily injection | GLP-1 RA | 2014 |
| Semaglutide (Wegovy) | ~14.9% (STEP-1, 68 wks) | Once weekly | GLP-1 RA | 2021 |
| Tirzepatide (Zepbound) | ~20.9% (SURMOUNT-1, 72 wks) | Once weekly | GLP-1 + GIP RA | 2023 |
Sources: SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015); STEP-1 (Wilding et al., NEJM 2021); SURMOUNT-1 (Jastreboff et al., NEJM 2022). Not directly cross-comparable — different populations, trial durations, and endpoints.
Who Should Consider Compounded Liraglutide?
Good candidates:
- Previously responded well to branded Saxenda and need continued access
- Physician has clinical reason to prefer liraglutide based on your medical history
- Insurance covers liraglutide but not semaglutide/tirzepatide (rare but possible)
- Transitioning from branded Saxenda to compounded version for cost savings
- Part of a structured metabolic protocol where liraglutide is indicated
Consider semaglutide or tirzepatide instead if:
- Starting GLP-1 therapy fresh with no prior liraglutide experience
- Maximum weight loss is the primary goal
- You want once-weekly injection rather than daily
- Your physician has no specific reason to recommend liraglutide over newer agents
- Cost is a major factor — compounded semaglutide starts at $99/mo
Regulatory Status of Compounded Liraglutide
503A compounding pharmacy preparation
Compounded liraglutide is legal under 503A pharmacy regulations when prepared with a valid patient-specific prescription. It is not FDA-approved but is not prohibited. Unlike compounded tirzepatide (which faced 503B restrictions in 2025 as the shortage was resolved), liraglutide's regulatory environment has been more stable.
Saxenda shortage history
Saxenda experienced periodic supply shortages during the GLP-1 demand surge of 2022–2024. Compounding interest was partly driven by these shortages. Current branded availability should be verified with your pharmacy. Compounded liraglutide provides an alternative when branded supply is limited.
Providers Offering Compounded Liraglutide
Verified May 6, 2026Very few telehealth providers currently offer compounded liraglutide. Verify availability directly — formularies can change.
Pricing: verify directly
Ivim Health explicitly offers compounded liraglutide as part of their GLP-1 formulary — making them one of the few telehealth providers to do so. Also known for customized microdosing protocols across their full GLP-1 lineup.
- Liraglutide in formulary (verify at intake)
- Customized dosing protocols
- Physician-supervised program
Primarily semaglutide/tirzepatide
TMates focuses on compounded semaglutide and tirzepatide. If you specifically need liraglutide, ask about availability during your intake consultation — formulary options can be discussed with their physician team.
Metabolic panel + physician oversight
Eden Health offers comprehensive metabolic monitoring. Ask about liraglutide availability at intake if you have specific clinical reasons for needing it over semaglutide or tirzepatide.
Affiliate disclosure: GLP1CompareHub earns a commission if you click through and enroll. See affiliate disclosure.
Frequently Asked Questions
What is compounded liraglutide?
Compounded liraglutide is a 503A compounding pharmacy preparation of liraglutide — the active ingredient in Saxenda (obesity) and Victoza (type 2 diabetes). It contains the same active peptide as the branded products but is prepared by a licensed compounding pharmacy and dispensed with a physician prescription. Compounded liraglutide is not FDA-approved but is legal under 503A pharmacy regulations.
How much weight loss does liraglutide produce?
In the SCALE Obesity and Prediabetes trial (published NEJM 2015), liraglutide 3mg daily produced approximately 8% weight loss at 56 weeks compared to ~2.6% with placebo. About 63% of patients lost at least 5% of body weight. This is substantially lower than what newer GLP-1 agents show: semaglutide (Wegovy) produces ~14.9% at 68 weeks (STEP-1), and tirzepatide produces ~20.9% at 72 weeks (SURMOUNT-1).
How does liraglutide compare to semaglutide for weight loss?
Liraglutide (Saxenda 3mg/day) produces approximately 8% weight loss in clinical trials vs approximately 14.9% for semaglutide 2.4mg/week (Wegovy). Both are GLP-1 receptor agonists, but semaglutide has a longer half-life (weekly injection vs daily for liraglutide) and higher receptor binding affinity. Semaglutide and tirzepatide are generally preferred for obesity treatment today due to their superior efficacy and more convenient dosing schedules.
Who should consider compounded liraglutide?
Liraglutide may be appropriate for patients who: (1) previously responded well to Saxenda and want continued access at lower cost; (2) have specific contraindications to semaglutide or tirzepatide based on their physician's assessment; (3) prefer a shorter-acting daily injection for flexibility in dosing management; or (4) are in a transition period from branded Saxenda. Most new patients will be directed to semaglutide or tirzepatide given their superior efficacy profiles.
Is liraglutide a daily injection?
Yes. Liraglutide (both Saxenda and Victoza) requires a daily subcutaneous injection. This contrasts with semaglutide (Ozempic/Wegovy), which is injected once weekly, and tirzepatide (Mounjaro/Zepbound), which is also once weekly. For patients who find daily injections burdensome, weekly semaglutide or tirzepatide may be more suitable.
Which telehealth providers offer compounded liraglutide?
Ivim Health is among the few telehealth providers that explicitly includes compounded liraglutide in their formulary. Most telehealth providers focus on compounded semaglutide and tirzepatide given their superior efficacy — liraglutide is a more niche offering. Verify availability directly with any provider, as formularies change.
Compare GLP-1 Options
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.